International Expansion By Ciba

18 December 1995

Ciba of Switzerland's eye care business, Ciba Vision, along with the Ciba-Geigy Foundation for Cooperation with Developing Countries, has announced a five-year program, valued at around 3.5 million Swiss francs ($3 million), to contribute significantly to training for eye care professionals in China and safeguard the optical health of Chinese contact lens wearers.

The company is also understood to be looking at making India a sourcing base for its global requirements, with plans for clinical research and the introduction of a new range of over-the-counter drugs.

Alex Krauer, chairman of Ciba, recently spent two days visiting the country for discussions on expansion of the business in India, according to local reports. Ciba's generic business, Geneva, may source its requirements in India, Mr Krauer is reported to have indicated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight